首页> 外文期刊>Clinical and experimental allergy : >A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects
【24h】

A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects

机译:吸附酪氨酸 Dermatophagoides pteronyssinus 抗原对照试验:体内方面

获取原文
获取外文期刊封面目录资料

摘要

SummaryContinuing study for a second year and further analysis of a double‐blind placebo controlled trial, already briefly reported, of injections of tyrosine‐adsorbed, glutaraldehyde‐modifiedDermatophagoides pteronyssinusantigen in fifty‐one children with perennial asthma and positive bronchial challenge to the antigen, confirms that the patients receiving the treatment reduced their symptomatic medication more than controls, without deterioration of symptoms. Some became symptom‐free, when off all treatment.A double‐blind placebo controlled trial of continuing treatment for a second year gave evidence of deterioration when the treatment was stopped.Within the treatment group, the improvement was associated with loss of late (6 hr) reaction to bronchial provocation with the antigen, but was not associated with change of immediate (20 min) reaction in lungs or skin. Those who improved in the placebo group did not lose their late reaction.There was a trend for similar benefit from active treatment in the control group, during the second year, though less than in the original active group, and only one lost his late reaction.Only one of the six children with very severe early onset asthma improved.Local reactions to either active or placebo (tyrosine) were seen in half the patients; these were mild and did not influence the treatment. Systemic symptoms occurred shortly after four active injections and after two placebo injections; only one patient stopped th
机译:摘要对一项双盲安慰剂对照试验的第二年持续研究和进一步分析,该试验在51名患有常年性哮喘和支气管对抗原阳性的儿童中注射酪氨酸吸附、戊二醛修饰的噬肤剂翼窦抗原,证实接受治疗的患者比对照组减少了对症药物,而症状没有恶化。有些患者在停止所有治疗后变得无症状。一项持续治疗第二年的双盲安慰剂对照试验提供了停止治疗后恶化的证据。在治疗组中,改善与抗原对支气管激发的晚期(6 小时)反应丧失有关,但与肺部或皮肤立即(20 分钟)反应的变化无关。那些在安慰剂组中有所改善的人并没有失去他们的迟到反应。在第二年,对照组的积极治疗有类似的益处趋势,尽管低于原始活性组,并且只有一人失去了迟到反应。在六名患有非常严重的早发性哮喘的儿童中,只有一名有所改善。在半数患者中观察到对活性或安慰剂(酪氨酸)的局部反应;这些是轻微的,不影响治疗。全身症状在四次主动注射和两次安慰剂注射后不久出现;只有一名患者停止了治疗

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号